Miami Cancer Institute names Yuliya Linhares, M.D., Chief of Lymphoma Services

MIAMI – September 23, 2019 — Medical oncologist and clinical researcher Yuliya Linhares, M.D., has been named Chief of the Lymphoma Service at Miami Cancer Institute at Baptist Health South Florida, the state’s only member of the Memorial Sloan Kettering Cancer Alliance. Dr. Linhares specializes in the comprehensive treatment of lymphoma, including expertise in both autologous and allogeneic stem cell transplantation. She also has unique experience with chemotherapy and stem cell transplantation using bloodless techniques, important for patients whose religious beliefs do not allow the use of blood transfusions.

Dr. Linhares is triple board certified by the American Board of Internal Medicine in internal medicine, hematology and medical oncology. She earned her medical degree at the University of North Carolina School of Medicine in Chapel Hill, N.C., graduating with distinction. She completed a residency in internal medicine and a fellowship in hematology-oncology at the University of California – Los Angeles. Prior to joining Miami Cancer Institute, Dr. Linhares treated patients in the Blood and Marrow Transplant Program at Cedars-Sinai Medical Center in Los Angeles.

“We are pleased that Dr. Linhares is bringing her tremendous talents to Miami Cancer Institute,” said Michael J. Zinner, M.D., CEO and executive medical director of Miami Cancer Institute. “She will lead our highly skilled multidisciplinary team to deliver the most advanced, personalized cancer care to patients with all subtypes of lymphoma.”

Dr. Linhares has extensive teaching experience training medical students, residents and oncology fellows at UCLA School of Medicine. She serves as an editorial reviewer for prestigious peer-reviewed scientific publications, is widely published in numerous medical journals for and delivers at invited lectures at academic symposia. Dr. Linhares is a member of American Society of Hematology and the American Society for Blood and Marrow Transplantation.

About Miami Cancer Institute
Miami Cancer Institute is Florida’s only next-generation cancer treatment destination, known for its personalized clinical care and research, compassionate patient experience and state-of-the-art technology – including the first proton therapy center in South Florida, Latin America and the Caribbean, and the only radiation oncology program in the world with each of the latest radiation therapies in one place. The Institute offers an impressive roster of established community oncologists and renowned cancer-fighting experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. As Florida’s only member of the Memorial Sloan Kettering (MSK) Cancer Alliance, Miami Cancer Institute is part of a deep and functional collaboration that affords patients access to innovative treatments right here at home and ensures that the standards of care developed by our multidisciplinary disease management teams match those at MSK.

Miami Cancer Institute is part of Baptist Health South Florida, the largest healthcare organization in the region, with 11 hospitals, nearly 23,000 employees, more than 4,000 physicians and more than 100 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and Baptist Health Care On Demand, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies. For more information, visit BaptistHealth.net/Newsroom and connect with us on Facebook, Instagram, Twitter and LinkedIn.

# # #